311 related articles for article (PubMed ID: 15292285)
21. Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131).
Coburn M; Teates D; Wanebo HJ
Ann Surg; 1994 Jun; 219(6):587-93; discussion 593-5. PubMed ID: 8203968
[TBL] [Abstract][Full Text] [Related]
22. Thyroid remnant ablation: questionable pursuit of an ill-defined goal.
Snyder J; Gorman C; Scanlon P
J Nucl Med; 1983 Aug; 24(8):659-65. PubMed ID: 6875677
[TBL] [Abstract][Full Text] [Related]
23. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
24. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
25. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer.
Juweid ME; Tulchinsky M; Mismar A; Momani M; Zayed AA; Al Hawari H; Albsoul N; Mottaghy FM
Int J Cancer; 2020 Nov; 147(9):2345-2354. PubMed ID: 32319676
[TBL] [Abstract][Full Text] [Related]
26. The evolving use of radioiodine therapy in differentiated thyroid cancer.
Mayson SE; Yoo DC; Gopalakrishnan G
Oncology; 2015; 88(4):247-56. PubMed ID: 25503797
[TBL] [Abstract][Full Text] [Related]
27. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
Yap BK; Murby B
J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
[TBL] [Abstract][Full Text] [Related]
28. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
Bal CS; Kumar A; Pant GS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
[TBL] [Abstract][Full Text] [Related]
29. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis.
Vardarli I; Weidemann F; Aboukoura M; Herrmann K; Binse I; Görges R
BMC Cancer; 2020 Jun; 20(1):550. PubMed ID: 32539683
[TBL] [Abstract][Full Text] [Related]
30. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
31. Natural history, treatment, and course of papillary thyroid carcinoma.
DeGroot LJ; Kaplan EL; McCormick M; Straus FH
J Clin Endocrinol Metab; 1990 Aug; 71(2):414-24. PubMed ID: 2380337
[TBL] [Abstract][Full Text] [Related]
32. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
Doi SA; Woodhouse NJ
Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
[TBL] [Abstract][Full Text] [Related]
33. Improving postoperative recurrence rates for carcinoma of the thyroid gland.
McHenry C; Jarosz H; Lawrence AM; Paloyan E
Surg Gynecol Obstet; 1989 Nov; 169(5):429-34. PubMed ID: 2814754
[TBL] [Abstract][Full Text] [Related]
34. Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.
Ain KB
Endocrine; 2015 Sep; 50(1):61-6. PubMed ID: 26109472
[TBL] [Abstract][Full Text] [Related]
35. Radioactive Iodine for Papillary Thyroid Carcinoma.
Chan WWL; Kwong DLW
Methods Mol Biol; 2022; 2534():225-241. PubMed ID: 35670979
[TBL] [Abstract][Full Text] [Related]
36. [Prospective therapy study in differentiated thyroid carcinoma].
Gemsenjäger E; Heitz P; Martina B
Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
[TBL] [Abstract][Full Text] [Related]
37. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer.
Vaisman F; Shaha A; Fish S; Michael Tuttle R
Clin Endocrinol (Oxf); 2011 Jul; 75(1):112-9. PubMed ID: 21521273
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
40. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
